On Dec. 18, 2020, Johnson & Johnson announced that its subsidiary Janssen Pharma, will provide up to 500 million doses of its investigational COVID-19 vaccine candidate as part of an agreement in principle with Gavi, The Vaccine Alliance (Gavi).

Gavi is the leading multilateral organization responsible for equitable access to vaccines and coordination of procurement and distribution of COVID-19 vaccines, including to lower-income countries, via the COVAX Facility. These doses were to be distributed through 2022, if the vaccine candidate was proven to be safe and effective.